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Highlights 
 Genetic-neuroimaging paradigms may aid in the understanding of the 
neurobiology of heterogeneous phenotypes like bipolar disorder; 
 A systematic review of gene-imaging studies conducted in samples with bipolar 
disorder was performed; 
 Forty-four studies (N=2,122 participants with bipolar disorder) met inclusion 
criteria; 
 Replicated evidence suggests that individuals with BD who carry the BDNF 
Val66Met allele may have smaller hippocampi volumes; 
 Studies that employed a genome-wide associated approach failed to reveal 
statistically significant findings. 
 
Abstract 
Genetic-neuroimaging paradigms could provide insights regarding the pathophysiology 
of bipolar disorder (BD). Nevertheless, findings have been inconsistent across studies. 
A systematic review of gene-imaging studies involving individuals with BD was 
conducted across electronic major databases from inception until January 9th, 2017. 
Forty-four studies met eligibility criteria (N=2,122 BD participants). Twenty-six gene 
variants were investigated across candidate gene studies and 4 studies used a genome-
wide association approach. Replicated evidence (i.e. in >2 studies) suggests that 
individuals with BD carrying the BDNF Val66Met risk allele could have reduced 
hippocampal volumes compared to non-carriers. This review underscores the potential 
of gene-neuroimaging paradigms to provide mechanistic insights for BD. However, this 
systematic review found a single replicated finding. Suggestions to improve the 
reproducibility of this emerging field are provided, including the adoption of a trans-
diagnostic approach. 
Abbreviations 
Anterior cingulum, AC; Adverse Childhood Experiences, ACE; Anterior cingulate 
gyrus, ACG; Anterior limb of internal capsule, ALIC; Ankyrin 3, ANK3; Bipolar 
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disorder, BD; Brain-derived neurotrophic factor, BDNF; Blood oxygen level dependent, 
BOLD; Calcium voltage-gated channel subunit alpha1 C, CACNA1C; Corpus 
callosum, CC; Corpus Callosum, body, CCb; Corpus Callosum, genu, CCg; Cingulate 
gyrus, CG; 2',3'-Cyclic-nucleotide 3'-phosphodiesterase, CNP; Catechol-O-
methyltransferase, COMT; Corona radiata, CR; Corticospinal tract, CST; D-amino acid 
oxidase, DAAO; D-amino acid oxidase actiqvator, DAOA; Diacylglycerol kinase eta, 
DGKH; Disrupted in schizophrenia 1, DISC1; Dorsolateral prefrontal cortex, dlPFC; 
Default mode network, DMN; Docking protein 5, DOK5; Diffusion tensor imaging, 
DTI; Excitatory amino-acid transporter 2, EAAT2; Erb-B2 Receptor Tyrosine Kinase 2, 
ERBB2; Fractional anisotropy, FA; Forceps major, FM; Functional MRI, fMRI; 
Fusiform gyrus, FG; Fronto-occipital fasciculus, FOF; Gamma-Amino Butyric Acid, 
GABA; Polypeptide N-Acetylgalactosaminyltransferase 7, GALNT7; Gyrification 
index, GI; Grey matter, GM; Globus pallidus, GP; Glutamate ionotropic receptor 
NMDA type subunit 2B, GRIN2B; Glycogen synthase kinase 3 beta, GSK-3β; 
Genome-wide association study, GWAS; Risk haplotype at the 5' end of the NRG1 
gene, HAP; Healthy controls, HCs; Inferior cerebellar peduncle, ICP; Interleukin-1 
beta, IL-1β; Inferior parietal lobule, IPL; Inferior occipital gyrus, IOG; Lateral 
ventricles, LV; Longitudinal fasciculus, LF; Minor allele, MA; Middle cerebellar 
peduncle, MCP; Mean diffusivity, MD; Myelin oligodendrocyte glycoprotein, MOG; 
Medial prefrontal cortex, mPFC; Magnetic resonance imaging, MRI; Middle temporal 
gyrus, MTG; Nucleus accumbens (NAc), NA; N-methyl-D-aspartate, NMDA; 
Neuregulin 1, NRG1; Teneurin transmembrane protein 4, ODZ4; Orbitofrontal cortex, 
OFC; Posterior cingulate gyrus, PCG; Prefrontal region, PF; Prefrontal cortex, PFC; 
Polygenic risk score, PGR; Parahippocampal gyrus, PHG; Radial diffusivity, RD; SZ, 
Schizophrenia; Serotonin-transporter-linked polymorphic region, 5-HTTLPR; Single 
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nucleotide polymorphism, SNP; Spectrin repeat containing nuclear envelope protein 1, 
SYNE1; Sterol regulatory element-binding transcription factor 1, SREBF1; Sterol 
regulatory element-binding transcription factor 2, SREBF2; Superior Temporal Gyrus, 
STG; Tract-based spatial statistics, TBSSBD; Tumor necrosis factor, TNF; Temporal 
pole, TP; Thalamic radiation, TR; Uncinate fasciculus, UF; Voxel-based morphometry, 
VBM; Ventrolateral prefrontal cortex, vlPFC; White matter, WM; Zinc finger protein 
804A, ZNF804A 
Key words: Bipolar disorder; genetic polymorphisms; neuroimaging; magnetic 
resonance imaging; functional MRI; diffusion tensor imaging, voxel-based 
morphometry. 
 
1. Introduction 
Bipolar disorder (BD) may affect approximately 2.4% of the population worldwide, and 
is associated with significant disability and elevated mortality rates compared to the 
general population (Grande et al., 2016; Hayes et al., 2015; Merikangas et al., 2011). 
The pathophysiology of BD has not been completely elucidated, and the current state of 
knowledge on putative mechanisms underpinning different clinical features and illness 
trajectories is limited (Craddock and Sklar, 2013; Hasler and Wolf, 2015). Several lines 
of evidence indicate that hereditary factors play a relevant role in the patho-etiology of 
BD, with phenotypic concordance rates ranging from 40-70% in monozygotic twins, 
and 8-10% in first-degree relatives (FDRs) (Kerner, 2014; Smoller and Finn, 2003). 
Genome-wide significant loci for BD have emerged from meta-analyses of GWAS, 
while loci near the TRANK1, ANK3, ODZ4, CACNA1C, and NCAN genes had at least 
one additional replication (Goes, 2016; Green et al., 2013; Muhleisen et al., 2014). A 
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recent GWAS identified two additional novel loci associated with bipolar disorder i.e. 
an inter-genic region on 9p21.3 and markers within ERBB2 (Hou et al., 2016). In 
addition, the CACNA1C gene differed in expression in the prefrontal cortex of patients 
with BD compared to controls (Nurnberger et al., 2014). However, identified genome-
wide significant signals seem to explain a low proportion of phenotypic variance of BD 
(Goes, 2016), and a polygenic risk score accounts for only 3% of its phenotypic 
variance (Group, 2011). It has been proposed that the effects of risk genes for BD could 
be larger and more evident on intermediate phenotypes neurobiologically linked to the 
disorder, thus providing an impetus to the emergence of ‘gene imaging’ studies in the 
literature (Bigos and Weinberger, 2010; Gurung and Prata, 2015; Ivleva et al., 2010).  
Precise mechanisms through which genetic variations may influence neural 
pathways accounting for the phenotypic heterogeneity of BD are yet to be established. 
Significant efforts have been conducted to identify phenotypic characteristics that are 
thought to lie more proximal to the genetic factors (i.e. endophenotypes) with the aim 
that this approach would aid in the identification of biological mechanisms of BD 
(Gottesman and Gould, 2003; Kurnianingsih et al., 2011). In this context, a large body 
of literature indicates that BD is associated with significant functional and structural 
neuroimaging alterations (Kempton et al., 2011; Kupferschmidt and Zakzanis, 2011). 
Furthermore, meta-analytic evidence indicates that functional and structural 
neuroimaging abnormalities may be evidence  in individuals at-risk for BD (Fusar-Poli 
et al., 2012), and a recent systematic review indicates that functional and structural 
neuroimaging abnormalities are also evident in healthy FDRs of patients with BD 
(Piguet et al., 2015). Altogether this literature provides support to the view that subtler 
functional and structural neuroimaging abnormalities in at-risk individuals could 
represent vulnerability markers of BD. ‘Imaging genetics’ has emerged as a field with 
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an underlying rationale that genetic variations that confer risk to mental disorders may 
exhibit higher penetrance at such brain functional/structural alterations than at the more 
distal psychopathological/behavioral levels (Hashimoto et al., 2015; Rasetti and 
Weinberger, 2011). Hence, an ever-increasing number of studies has attempted to 
investigate the associations between genetic variations expected to play a 
pathophysiological role in BD and structural and functional neuroimaging 
abnormalities. However, different age groups, neuroimaging modalities, treatment-
related effects and investigated genes (or polygenic risk scores) are potential 
confounders which might have contributed to the heterogeneity of studies so far 
(Kurnianingsih et al., 2011). To overcome such a strong heterogeneity a systematic 
review of ‘neuroimaging genetics’ studies which considered genes which have been 
previously found to reach genome-wide significance in schizophrenia and BD was 
conducted (Gurung and Prata, 2015; Lee et al., 2012). However, this previous 
systematic review considered studies performed solely in healthy individuals, while 
only seven studies performed in samples with BD were included (Gurung and Prata, 
2015). A comprehensive systematic overview focusing on ‘imaging genetics’ 
specifically in people with BD is currently lacking.   
Therefore, our systematic review aims to provide a comprehensive and up-dated 
synthesis of all available ‘imaging genetics’ literature in BD. Both structural and 
functional magnetic resonance imaging studies will be considered. Our goal was two-
fold: (1) to summarize and facilitate the integration of findings in this evolving field; 
and (2) to provide an illustrative structural and functional brain map of significant BD-
associated gene risk variants, which are expected to be linked to brain regions with 
known alterations in BD. 
2. Methods 
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A systematic literature search of genetic variations and functional and structural 
magnetic resonance imaging (MRI) studies in BD was conducted. We followed the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement (Moher et al., 2010), using an a priori defined but unpublished protocol. 
2.1. Search strategy 
The EMBASE, PubMed/MEDLINE and PsycINFO electronic databases were searched 
from inception up to January 9th, 2017. The following search string was used: (bipolar 
disorder OR mania OR bipolar depression) AND (structural magnetic resonance OR 
functional magnetic resonance OR fMRI OR BOLD fMRI OR magnetic resonance 
imaging OR magnetic resonance neuroimaging OR tractography) AND (SNPs OR 
single nucleotide polymorphism OR haplotypes OR gene expression OR gene OR 
genetic score OR genetic* OR methylome OR epigenetic* OR genome OR 
transcriptome OR polymorphism OR genetic polymorphism OR genome wide OR 
genome-wide). In addition, the reference lists of eligible articles were hand searched to 
identify additional eligible references. 
2.2. Eligibility Criteria 
The articles included in this review fulfilled the following criteria: (1) human studies 
with participants at any age with a diagnosis of type I BD (BD-I), type II BD (BD-II), or 
BD not otherwise specified (BD-NOS) using standard diagnostic criteria (DSM-IV, 
ICD-10 or Research Diagnostic Criteria regardless of the current mood state (euthymic, 
manic or depressed); (2) combined investigations of genetic factors and brain imaging 
protocols (structural or functional). The included articles had to investigate imaging-
genetic associations of BD patients that were carriers of high-risk alleles compared to 
either healthy controls (HC) and/or BD patients who were non-carriers of the 
8 
 
investigated risk alleles. No language restrictions were applied. Studies that reported a 
sub-analysis of a well-defined sample of participants with BD within a broad mood 
disorder group were also eligible. 
Animal and post-mortem studies, case series, literature reviews, conference 
papers, meeting abstracts or meta-analyses were excluded. Studies which included 
samples with mixed diagnoses were excluded, unless data for participants with BD were 
separately provided. Articles that used imaging methods other than structural or 
functional MRI (e.g., magnetic resonance spectroscopy or positron emission 
tomography) were also excluded. 
 
 
2.3. Study Selection 
Two investigators (LPP and BPF) independently screened the titles and abstracts of 
retrieved references for eligibility. Next, the full-texts of the selected references were 
obtained, and the same authors independently reviewed each article for final inclusion 
in this systematic review. Disagreements were resolved through consensus. Whenever a 
consensus could not be achieved, a third author (CAK) made the final decision 
regarding inclusion. The agreement between the two raters was high (83.7%). 
2.4. Data Extraction 
Two authors (LPP and BPF) independently extracted the data of selected papers using a 
standardized spreadsheet. The following variables were recorded: first author, year of 
publication, sample size, age of participants, % of females, diagnostic criteria for BD, 
genetic assessment (name of the gene, method, SNP and allele groups), imaging 
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methods and procedures, the experimental paradigm (in case of fMRI), MRI regions of 
interest (ROI) and the results of the association between the genetic variants and each 
ROI. Whenever the sample contained BD patients as part of a broader sample that 
included other psychiatric diagnoses, only data and associations of the BD group was 
extracted. The agreement between the two raters was 89.6%. 
2.5. Data synthesis 
Due to the anticipated heterogeneity and paucity of homogenous studies, meta-analysis 
of included studies was not feasible. Thus, we synthesized the included studies with a 
best evidence synthesis. First, we considered structural imaging studies and candidate 
genes and GWAS relationships. Second, we considered the relationship between 
functional imaging studies and candidate genes and GWAS studies. We considered 
evidence to be replicated or consistent when a relationship was evident between 2 
studies between a candidate gene/GWAS and a particular structural and/or functional 
neuroimaging abnormality. 
3. Results 
3.1 Search Results 
The literature search found 873 records, and 9 additional references were found through 
searching the reference lists of included articles. After the removal of duplicates, 632 
unique references were screened. Five hundred and seventy-one references were 
excluded after title/abstract screening. Of the 61 full-texts assessed, 17 were excluded 
due to: (1) not an original study (k = 2); (2) no data for BD participant was provided (k 
= 9), (3) not investigating samples with BD (k = 1), (4) no genetic measure (k = 1), (5) 
using other neuroimaging method not specified in the inclusion criteria (k = 2), (6) not 
investigating genetic-imaging associations in BD (k = 1) or (7) article not available (k = 
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1). Therefore, forty-four genetic-neuroimaging studies met inclusion criteria for this 
qualitative systematic review. Figure 1 presents the flowchart of study selection. The 
studies excluded during full-text review and reasons for exclusion are presented in 
Supplementary Table S1 that accompanies the online version of this article. 
<Please insert Figure 1 here> 
3.2 Overview of included studies 
All included studies are described in Tables 1 and 2 (structural MRI, k = 28) and Tables 
3 and 4 (fMRI, k = 16). Forty studies investigated 26 candidate risk genes for BD and 4 
studies used a genome-wide significance analysis. The studies altogether included 2,122 
participants with BD [BD group; age = 38.6 ± 13.6 years (mean ± SD); 56.6% female] 
and 2,389 healthy participants (HC group; age = 35.9 ± 12.4 years (mean ± SD); 53.0% 
female). All studies included only adult samples except for three studies that included 
only pediatric samples (Barzman et al., 2014; Liu et al., 2010; Zeni et al., 2016).  
Twenty-eight studies investigated structural changes using either VBM or DTI, and 16 
studies used functional MRI to investigate changes in brain activity associated. The 
functional studies were based on several tasks, including emotional processing of faces 
(k = 8), Posner emotional task (k = 1), verbal fluency tasks (k = 4), and working 
memory (k = 2). Emotional tasks included contrasts of the task-related activity and 
baseline, and within neutral and affective content. The other tasks compared task-related 
activity with baseline.  
<Please insert Table 1 here> 
<Please insert Table 2 here> 
<Please insert Table 3 here> 
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<Please insert Table 4 here> 
3.3. Structural imaging studies 
3.3.1. Candidate Genes 
Twenty-six studies investigated associations of 19 candidate genes with structural 
imaging data (see Table 1 for studies using VBM and Table 2 for studies using DTI). 
Except for the study by Zeni et al. (2016), all other studies included an adult sample. 
Eighteen studies investigated structural measures [total/regional brain volumes, cortical 
thickness and white matter (WM) integrity] using VBM, 6 studies focused on DTI 
metrics [e.g. fractional anisotropy (FA)] and 2 studies used both methods. The most 
frequently investigated genes were BDNF (5 studies, all VBM), CACNA1C (5 studies, 4 
VBM and 1 DTI), ANK3 (3 studies, 1 VBM and 2 VBM/DTI combined), 5-HTTLPR (3 
studies, 2 VBM and 1 DTI), ZNF804A (3 studies, 1 VBM and 2 DTI), and GSK-3β (2 
studies, 1 VBM and 1 DTI) (Table 1 and Table 2). The remaining genes (EAAT2, 
DGKH, NRG1, HAP, CNP, MOG, IL-1B, ODZ4, SYNE1, DAOA, GRIN2B, SREBF1 
and SREBF2) were investigated by a single study. 
Six studies included only participants with BD (i.e. carriers vs. non-carriers of 
genetic risk variants) (Benedetti et al., 2013; Benedetti et al., 2015a; Benedetti et al., 
2015b; Benedetti et al., 2014; Poletti et al., 2016; Poletti et al., 2014). Three of those 
studies investigated 5-HTTLPR (Benedetti et al., 2015a), GSK-3β (Benedetti et al., 
2013) or SREBF1/2 (Poletti et al., 2016) using DTI. Benedetti et al. (2015a) found that 
carriers of the 5-HTTLPR S (i.e., short) allele had increased radial and mean diffusivity 
in several brain white matter tracts, including the cingulum gyrus, corpus callosum 
(body and genum) and corona radiata compared to non-carriers. Significant increases in 
axial diffusivity measures were observed in carriers of the less active GSK3-β 
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rs334558*C gene-promoter variant in 70 participants with an index bipolar depressive 
episode across several white matter fiber tracts (Benedetti et al., 2013). Interestingly, 
lithium treatment (which inhibits GSK-3β) was also associated with similar changes in 
axial diffusivity, which points to a better integrity of axon and myelin sheaths 
(Benedetti et al., 2013). Poletti et al. (2016) found that carriers of the SREBF2 
rs1052717 polymorphism A/A genotype had increased radial diffusivity and reduced 
FA compared to G carriers in the cingulum, corpus callosum, superior and inferior 
longitudinal fasciculi, and anterior thalamic radiation. The remaining 3 studies 
investigated variations in the 5-HTTLPR (Benedetti et al., 2014), GSK-3β (Benedetti et 
al., 2015b) or EAAT2 (Poletti et al., 2014) genes using VBM. All three studies did not 
verify any significant genetic-imaging associations in BD.  
The other 19 studies included a HC comparison group. Fourteen of these studies 
found significant associations of brain structural changes and genetic variants, in both 
grey and white matter. These included associations of the BDNF (k = 4), 5-HTTLPR (k 
= 1), CACNAC1 (k = 1), DGKH (k = 1), NRG1 and HAPICE haplotype (k = 1), IL-1β (k 
= 1) with brain volumes using VBM, and also ANK3 (k = 2), 5-HTTLPR (k = 1), GSK-
3β (k = 1) and GRIN2B (k = 1) with white matter integrity using DTI. See section 3.5.1 
for details. 
3.3.2. Genome-Wide Association Studies 
Two studies used Genome-Wide Association Studies (GWAS) to identify genes 
associated with BD, and then investigated associations with structural changes using 
VBM (Bakken et al., 2011; Oertel-Knochel et al., 2015) (Table 1). Oertel-Knochel et al. 
(2015) investigated 7 SNPs obtained from a GWAS study in SZ (MIR137, CCDC68, 
CNNM2, NT5C2, MMP16, CSMD1 and PCGEM1) to identify genetic variants 
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associated with structural brain changes across the psychosis spectrum. No statistically 
significant association was observed for the group that included only participants with 
BD. Bakken et al. (2011) examined associations of 597,198 SNPs with average cortical 
thickness using the PLINK analytic tool (Purcell et al., 2007) to fit an additive linear 
model with minor allele counts, sex, age and diagnosis, using a conservative Bonferroni 
correction for genome-wide significance. No statistically significant imaging-genetic 
associations were found in the BD group. 
3.4. Functional Imaging studies 
3.4.1. Candidate Genes 
Fifteen studies investigated associations of variations in 11 candidate genes and blood 
oxygen level dependent (BOLD) fMRI. The most frequently investigated genes were 
CACNA1C (4 studies) and ANK3, DAAO and DISC1 (2 studies each) (Tables 3 and 4). 
The remaining genes (TNF, G72, BclI, COMT, DOK5, 5-HTTLPR and NRG1) were 
investigated in a single study. 
Barzman et al. (2014) investigated a small sample of pediatric BD patients, and 
found that the expression of 11 TNF-related genes in peripheral blood mononuclear 
cells of participants with BD significantly correlated with activation of the amygdala or 
anterior cingulate gyrus during the affective Posner task. 
All other studies included only adults, and included a HC group for comparison. 
Eight of these studies found significant gene × brain activity associations in BD 
patients. The CACNAC1 gene was associated with increased amygdala activation in the 
face recognition paradigm (k = 2). The ANK3 gene was associated with increased 
activity in the cingulate cortex during a working memory task (k = 1). Both the ANK3 
and CACNAC1 genes were associated with reduced activation of the vlPFC during the 
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emotional facial processing task (k = 1). The DISC1 gene was associated with 
decreased activation of the IPL and left CG during a verbal initiation and sentence 
completion task (k = 1). Also in a verbal fluency paradigm, the DAOA (k = 1) genotype 
was associated with a greater deactivation of the let precuneus in BD patients, while the 
NRG1 genotype was associated with increased activation of the right posterior OFC. 
Finally, the 5-HTTPLPR was associated with lower ventral anterior CG activity during 
emotional processing of faces (k = 1). See section 3.5.2 for details. 
3.4.2. Genome-Wide Association Studies 
Liu et al. (2010) investigated a sample of adolescents with BD and HCs of similar age. 
These authors performed a GWAS, and found that the rs2023454 SNP of the DOK5 
gene was associated with right amygdala activation under contrast to hostility faces 
although no significant differences between and within BD and HC samples were 
observed. Dima et al. (2016) calculated a polygenic risk score (PGR) from genes that 
were associated with BD in a GWAS. Although the PGR was associated with changes 
in brain activity during a facial processing task and a working memory task in both the 
BD and HC groups, no statistically significant differences emerged between the two 
groups or within the BD group as a function of the PGR. 
3.5. Significant genetic-neuroimaging associations in BD 
The statistically significant associations reported across genetic-neuroimaging studies 
using candidate genes are shown in Table 5. In addition, a brief synopsis of possible 
biological functions of gene products is provided.  
3.5.1. Structural VBM and DTI studies 
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Statistically significant structural neuroimaging alterations in BD patients were 
associated with genetic variations of the BDNF, 5-HTTLPR, CACNA1C, DGKH, NRG1, 
IL-1β, ANK3, and GRIN2B genes (Table 5). Nevertheless, there was a lack of replicated 
evidence.  
<Please insert Table 5 here> 
Two studies provided evidence that BD patients who carry the Met allele of the 
BDNF gene may present several structural alterations encompassing several brain areas 
namely the left and right hippocampus (Cao et al., 2016; Chepenik et al., 2009). A four-
year prospective study found that individuals BD participants who were carriers of one 
or more BDNF Met alleles had significantly greater losses in gyrification indexes, an 
effect that correlated with gray matter loss in the left hemisphere (Mirakhur et al., 
2009).  Matsuo et al. (2009) observed smaller bilateral anterior cingulate gyrus volumes 
in BD patients with Val/Met compared to those with Val/Val BDNF genotypes, while in 
both the BD and HC groups participants with the Val/Met BDNF genotype had smaller 
left and right gray matter volumes of the dorsolateral prefrontal cortex. 
Increased volumes of the left amygdala were observed in carriers of the S allele of 
the 5-HTTLPR gene both in BD and HC groups (Scherk et al., 2009a). 
Genetic variations in the CACNA1C genes were not associated with significant 
structural changes in three VBM studies (Soeiro-de-Souza et al., 2012; Tesli et al., 
2013; Wolf et al., 2014), whereas Perrier et al. (2011a) found that euthymic BD patients 
carrying the CACNA1C rs1006737 risk allele had a smaller volume of the left putamen 
compared HCs. 
A significantly increased volume of the left amygdala was associated with the 
DGKH haplotype (rs994856/rs9525580/rs9525584 GAT) in 30 euthymic patients with 
type I BD but not in HCs (Kittel-Schneider et al., 2015). The risk genotype (TT) of the 
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NRG1 SNP8NRG221533 was associated with reduced white matter volumes in the 
fornix, cingulum and para-hippocampal gyrus in a type I BD sample (Cannon et al., 
2012). In the same study, BD participants carrying one or two copies of the HAPICE 
haplotypes of the NRG1 gene had greater white matter volume than those carrying none 
in the fornix, caudate and cingulum (Cannon et al., 2012). Papiol et al. (2008) found 
that a -511C/T SNP (rs16944) of the IL-1β gene was associated with whole-brain and 
left dlPFC gray matter deficits in a sample of 20 participants with BD in a VBM study. 
Two studies found that distinct variations of the ANK3 gene were associated with DTI 
findings (reduced FA) compatible with widespread white matter deficits in several brain 
regions, such as the forceps minor, the uncinate fasciculus, the anterior cingulate gyrus, 
the dorsolateral frontal cortex, the left temporoparietal WM, and in posterior 
dorsomedial WM (Lippard et al., 2016; Ota et al., 2016). Finally, compared to the G 
allele of the GRIN2B gene, brain FA values were significantly lower in BD patients 
with risk T allele in left and right frontal regions, left parietal region, left and right 
occipital regions and the left cingulate gyrus (Kuswanto et al., 2013). 
3.5.2. fMRI studies 
Functional neuroimaging alterations were associated with genetic variations in the 
CACNA1C, ANK3, DISC1, TNF, DAOA, 5-HTTLPR and NRG1 genes (Table 5). 
The most frequent regions with functional alterations significantly associated with 
genetic variations in BD were: (1) the right anterior CG (ACG), where variation in the 
ANK3 and TNF genes were associated with greater activation in working memory tasks 
(ANK3) or Posner task (TNF), whereas the 5-HTTLPR S allele was significantly 
associated with lower activation during an emotional processing task; (2) the left ACG, 
where polymorphisms in the TNF gene were associated with increased activation and 
the 5-HTTLPR S allele with decreased activation during emotional processing tasks; (3) 
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left amygdala, where variation in the CACNA1C and TNF genes were associated with 
greater activation during emotional processing tasks; (4) left CG, where polymorphisms 
in DISC1 were associated with lower activation during a verbal fluency task; (5) left 
para-hippocampal gyrus, where ANK3 polymorphisms were associated with greater 
activation; and during a working memory task; and (6) the left vlPFC, where variations 
in both CACNA1C and 5-HTTLPR genes were associated with greater activation during 
emotional processing tasks. 
The fMRI paradigms that were most frequently used across functional 
neuroimaging studies with statistically significant genetic-imaging findings were 
emotional faces task (8 studies) and the verbal fluency test (2 studies). Three studies 
found associations of the CACNA1C risk allele A with an increase in activation of either 
left or right amygdala (Jogia et al., 2011; Tesli et al., 2013), and a hypoactivation of the 
vlPFC (Dima et al., 2013; Jogia et al., 2011), with one study reported both alterations 
(Jogia et al., 2011) in the emotional faces task. The remaining studies found decreased 
activation of the vlPFC in association with the ANK3 rs10994336 polymorphism risk 
allele T (Delvecchio et al., 2015) or a decreased activation of the ventral anterior 
cingulate gyrus related to the 5HTTLPR S risk allele (Shah et al., 2009). Studies that 
employed the verbal fluency test were inconsistent regarding both genetic variations and 
activated ROIs (Mechelli et al., 2012; Mechelli et al., 2008). 
3.5.3. Illustrative brain map of significant replicated gene-neuroimaging findings 
Figure 2 summarized replicated gene-imaging findings in BD patients in comparison to 
healthy controls. A difference was considered statistically significant (p < 0.05) only if 
the neuroimaging findings of BD patients carrying the risk allele were different from the 
HCs or BD subjects not carrying the risk allele (i.e., a gene x diagnosis interaction). 
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Two fMRI studies found that individuals with BD carrying the A variant of the 
CACNA1C Rs1006737 polymorphism had decreased activity in the right dorsal 
ventrolateral prefrontal cortex during the emotional faces paradigm. However, samples 
across those two investigations appeared to overlap (Dima et al., 2013; Jogia et al., 
2011), and thus this association was not regarded as a true replication. Furthermore, two 
VBM studies found that subjects BD who were carriers of the Met allele of the BDNF 
Val66Met polymorphism had decreased volumes of the left and right hippocampi (Cao 
et al., 2016; Chepenik et al., 2009). 
<Please insert Figure 2 here> 
3.6. Methodological considerations 
The minority of included studies enrolled only euthymic BD participants (k = 10; 
22.7%), while the mood status of participants with BD was clearly described in 21 
(47.7%) studies. Twenty studies (45.5%) controlled results for the effects of medication 
or otherwise included only drug-free BD participants, while most included studies 
controlled findings for multiple comparisons (k = 33; 75.0%). A healthy control group 
was included in 36 (81.8%) studies.  The median (IQR) sample sizes for VBM, DTI and 
fMRI studies were 80 (72-84), 153.5 (87.25-172) and 80.5 (69.5-87.25). A whole-brain 
analysis was conducted in 15 (34.0%) studies, while 18 (40.9%) studies performed only 
a priori defined ROI-based analyses, and 4 (9.1%) studies carried out both types of 
analyses. Twenty-eight studies used a 1.5T magnetic field, 13 studies used 3.0T, 1 study 
4.0T and 2 did not specify the magnetic field of the scanner. 
 
4. Discussion 
19 
 
The aim of this systematic review was to assess the extant literature reporting ‘imaging 
genetics’ findings in BD. We included both structural and functional MRI studies. The 
most frequently reported genes (at least 2 studies) with statistically significant 
neuroimaging alterations in BD patients were CACNA1C, ANK3, BDNF, 5-HTTLPR, 
NRG1 and DAOA. Of those genes, loci close to the CACNA1C and ANK3 genes have 
reached genome-wide significant associations with BD, and associations were 
replicated in at least one independent dataset (Goes, 2016). To our knowledge this effort 
represents the largest evidence-based synthesis to date of this field.  
Our findings suggest that the effects of genetic variants on intermediate 
neuroimaging phenotypes could be independent (i.e., pleiotropic) of effects on the 
clinical phenotype per se (Gottesman and Gould, 2003), which is consistent with the 
view that an endophenotypic approach may aid in the search of biological pathways 
underpinning heterogeneous mental disorders like BD (Miskowiak et al., 2016). The 
findings reviewed herein may at least partly explain that although at the population level 
BD is associated with a significant degree of both “cold” and “hot” (i.e., emotion-laden) 
(Miskowiak and Carvalho, 2014; Roiser et al., 2009) cognitive deficits, recent meta-
analyses point to a significant degree of heterogeneity (Bora and Pantelis, 2016; 
Bortolato et al., 2015; Bourne et al., 2013). Nevertheless, a certain degree of uncertainty 
lies on the precise pathways which could be influenced by those gene products with 
relevance to the underlying neurobiology of subsets of individuals with BD. 
Furthermore, one cannot exclude the possibility that those risk genetic variants are not 
inherently causal, but instead may be passed in linkage disequilibrium with causative 
ones. We observed that although several candidate gene studies reported significant 
associations with structural/functional neuroimaging findings, whilst the few studies 
that followed a GWAS methodology did not report statistically significant findings 
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(Bakken et al., 2011; Liu et al., 2010; Oertel-Knochel et al., 2015). Evidence indicates 
that the literature on structural and functional neuroimaging studies could be limited by 
an excess of significance bias (i.e., there is an excess of statistically significant 
findings), which may undermine the reproducibility of the field as a whole (Fusar-Poli 
et al., 2014; Ioannidis et al., 2014). In addition, a selective reporting of outcomes (i.e., 
only those genes with statistically significant findings are reported) could result in a 
type I error (Ioannidis et al., 2014). Moreover, sample sizes varied across studies, and 
due to the few studies available it is difficult to estimate the statistical power of 
individual studies. This aspect may also undermine the reproducibility of gene-imaging 
studies as discussed in detail elsewhere (Carter et al., 2016). Therefore, we focused our 
discussion on candidate genes with at least two statistically significant findings. 
Furthermore, we contextualized the main findings of our review with data derived from 
the preclinical and neuropsychological literature. 
4.1. The CACNA1C gene 
The CACNA1C gene encodes the L-type voltage-dependent calcium channel 1C 
subunit, and at least two GWAS have implicated its rs1006737 SNP as a risk variant 
associated with BD (Sklar et al., 2008). This association has been consistently replicated 
since then (Goes, 2016). Notwithstanding Perrier et al. (2011a) observed a significantly 
reduced volume of the left putamen in a sample of BD patients carrying the rs1006737 
SNP risk allele compared to HCs. However, two subsequent VBM studies failed to 
replicate those findings (Soeiro-de-Souza et al., 2012; Wolf et al., 2014).  
Significant within-group differences were observed in BD who were carriers of 
the risk allele of the CACNA1C gene after recognition of negative/fearful faces 
(compared to neutral faces) in the facial affect recognition task. For example, carriers of 
the risk allele had a higher activation of the left amygdala in one study (Tesli et al., 
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2013), while another study found higher activation of the amygdala bilaterally in the 
same task (Jogia et al., 2011). Furthermore, two studies found an hyperactivation of the 
left ventrolateral prefrontal cortex in the same experimental paradigm (Dima et al., 
2013; Jogia et al., 2011). Nevertheless, another study did not report significant 
functional brain abnormalities related to this risk allele in the facial emotion recognition 
task (Radua et al., 2013). Methodological differences across studies may explain those 
discrepant findings. For example, Radua et al. (2013) did not explicitly exclude BD 
participants with co-occurring somatic and mental disorders. Furthermore, there was an 
overlap in samples included in the studies carried out by Jogia et al. (2011) and Dima et 
al. (2013). Ou et al. (2015) postulated that the lack of significant differences in 
neuroimaging studies between participants with BD and HCs as a function of the 
CACNA1C risk allele could be due to differences in the prevalence of cardiovascular 
risk factors. Therefore, differences in eligibility criteria across studies may at least in 
part explain contrasting results across studies. Nevertheless, those functional brain 
abnormalities as a function of the presence of the AA/AG CACNA1C risk alleles are 
consistent with the neuropsychological literature. Hence although less unanimous than 
the neuroimaging literature, BD patients who carry those risk alleles may score poorer 
on speed of processing and digit span tests compared to non-carriers (consistent with a 
lower efficiency of the left ventrolateral prefrontal cortex). In addition, carriers of the 
risk allele may display impaired recognition of emotional faces (disgust, sadness, 
happiness, and anger) [see Ou et al. (2015) for a review]. 
4.2. The ANK3 gene 
The ANK3 gene codes for Ankyrin G, a protein which may be involved in the 
stabilization and localization of ion channels and cell adhesion molecules to nodes of 
Ranvier and initial segments of axon (Gasser et al., 2012). Furthermore, an elegant 
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preclinical study found a lack of voltage-gated sodium channels in GABAergic 
parvalbumin interneurons in mice deficient of exon 1b of the ANK3 (Lopez et al., 2016). 
Consistently, mice exhibited an ANK3 gene dose-dependent phenotype characterized by 
manic-like behavior, epilepsy, and sudden death (Lopez et al., 2016).  In addition, 
Ankyrin G has been implicated in neurodevelopment, and in the onset of myelination 
(Ching et al., 1999), and also in the regulation of neurogenesis (Durak et al., 2015; 
Leussis et al., 2012). 
Replicated findings indicate that different risk alleles of the ANK3  gene may 
impact white matter structure in BD. For example, BD patients who were carriers of the 
risk allele rs10761482 SNP had decreased FA in the forceps minor (Ota et al., 2016), 
while BD patients who were carriers of the risk allele of the rs9804190 had decreased 
FA in the uncinate fasciculus and the cingulate gyrus bilaterally among other regions 
compared to CC homozygotes (Lippard et al., 2016). These findings are consistent with 
a recent meta-analysis of DTI studies in BD which evidences widespread white matter 
in this illness compared to controls (Nortje et al., 2013). Greater widespread 
abnormalities in individuals with BD carrying risk variants of the ANK3 gene also 
provide support for a putative role of Ankyrin G in myelination. In addition, risk alleles 
of this gene could lead to accelerated brain aging in BD (Rizzo et al., 2014). 
Furthermore, the risk C-allele of rs10761482 SNP was significantly associated with 
worse performance on verbal comprehension, logical memory and processing speed in 
BD patients in one study (Hori et al., 2014), while another study found that the risk 
allele of the rs10994336 SNP was associated with reduced sensitivity in target detection 
and increased errors of commission during sustained attention in both patients with BD 
and HCs (Ruberto et al., 2011). Altogether, these data suggest that different risk alleles 
of the ANK3 gene could have a deleterious effect on WM structure in BD, which could 
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be related to neurocognitive deficits. This hypothesis is further supported by a study that 
found that the risk allele of the rs10994336 SNP was associated with hyperactivation of 
the right anterior cingulate cortex and left posterior cingulate cortex in patients with BD 
compared to HCs in the N-back test, which measures executive function (Delvecchio et 
al., 2015).  
4.3. The BDNF gene 
The brain-derived neurotrophic factor (BDNF) gene is located on chromosome 11p14.1. 
The BDNF protein is a member of the neurotrophin superfamily, which supports 
neuronal survival, neural differentiation during development, and has been implicated in 
the regulation of activity dependent-synaptic plasticity in mature neurons (Duman and 
Monteggia, 2006; Hempstead, 2015). This neurotrophin is abundantly expressed in the 
hippocampus (Duman and Monteggia, 2006). The BDNF rs6265 SNP has been 
frequently investigated and an alteration at nucleotide 196 (G/A) which produces a 
Val66Met substitution (Notaras et al., 2015a). This SNP may result in a diminished 
cellular trafficking and packaging of the mature BDNF protein into the secretory 
vesicles, thus reducing depolarization-induced release of this neurotrophin (Notaras et 
al., 2015a). Furthermore, carriers of this risk SNP could produce the Met BDNF 
prodomain in larger amounts, with may have opposing effects (i.e., a negative impact in 
neuron architecture remodeling) via an activation of the p75 and sortilin-related VPS10 
domain containing receptor 2 (SorCS2) receptors (Hempstead, 2015). Consistently, this 
systematic review found replicated evidence that carriers of the BDNF met allele 
exhibit smaller hippocampal volumes (Cao et al., 2016; Chepenik et al., 2009). In one 
study BD carriers of this risk allele presented smaller hippocampal volumes compared 
to HCs (Cao et al., 2016), whereas in carriers of the Met allele had smaller hippocampus 
regardless of diagnostic group (i.e., BD or HC) (Chepenik et al., 2009). Zeni et al. 
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(2016) studied a sample of pediatric patients with BD, and found that the Met allele of 
the BDNF gene had no influence on hippocampal volumes. A potential explanation for 
this finding is that this SNP could influence hippocampal volume over time as 
suggested by a previous study (McIntosh et al., 2007). A previous meta-analysis found 
that neuropsychiatric patients with either the Val/Val genotype or Met-carriers had 
significantly smaller hippocampal volumes compared to HCs with the same genotypes 
(Harrisberger et al., 2015). Therefore, it is possible that the Met risk allele could 
mediate within group differences in BD samples, but not differences between 
participants with BD and HCs.  
A recent meta-analysis suggests that the BDNF Val66Met SNP is not associated 
with BD (Gonzalez-Castro et al., 2015), although this association could be significant in 
European populations (Li et al., 2016).  This highlights that the effects of the Met allele 
of the BDNF gene could be more readily demonstrated at the neuroimaging or 
neuropsychological level than at the diagnostic level. Hence, several studies suggest that 
individuals with BD carrying the Met allele could have worse cognitive function in 
several domains including memory (Cao et al., 2016; Rybakowski et al., 2003; 
Rybakowski et al., 2006; Tramontina et al., 2009), although this association has not 
been unanimously demonstrated across studies (Rolstad et al., 2016; Rosa et al., 2014). 
These discrepancies may be related to the influence of concomitant medication (Grande 
et al., 2014). Furthermore, the involvement of BDNF in the pathophysiology of BD is 
supported by a recent meta-analysis which found that peripheral levels of this protein 
could be a biomarker of illness activity (Fernandes et al., 2015). Finally, preclinical 
evidence points to a role for BDNF in BD (de Souza Gomes et al., 2015; Macedo et al., 
2012). 
4.4. The 5-HTTLPR gene 
25 
 
A functional polymorphism (5-HTTLPR) in the promoter of serotonin transporter gene 
(SLC6A4) has been described in 1996 (Lesch et al., 1996). Since then, the impact of this 
polymorphism in a range of mental disorders and intermediate phenotypes have been a 
focus of  substantial research efforts [see Jonassen and Landro (2014) for a review]. In 
addition, evidence suggests that methylation of the serotonin transporter gene may 
provide an epigenetic marker of exposure to life adversities (Provenzi et al., 2016). 
Notwithstanding the 5-HTTLPR polymorphism does not seem to affect the methylation 
status of the SLC6A4 gene, preliminary evidence suggests a possible interaction of 
methylation status and the short (S) allele in the development of stress-related mood 
disorders (Olsson et al., 2010). 
Benedetti et al. (2014) observed that the S allele of the 5-HTTLPR mediated the 
effect of early life stress on gray matter volumes in the right prefrontal cortex in a 
sample with BD. Furthermore, the S allele was also associated with higher right 
amygdala volumes in both patients with BD and HCs. Notwithstanding a previous 
meta-analysis suggests that the S allele could lead to amygdala hyperactivation in 
emotional paradigms (Murphy et al., 2013), our systematic review did not find a study 
to replicate this finding in BD. Nevertheless, one study found that S carriers had lower 
ventral anterior cingulate cortex activation compared to L/L participants during 
processing of happy and fear faces; this effect was evident in both the HC and BD 
groups (Shah et al., 2009). Clearly effects of the ‘S’ 5-HTTLPR on intermediate 
phenotypes in BD deserve further investigation. 
4.5. The NRG1 gene 
Evidence indicates that neuregulin 1 and its cognate receptor ErB4 play significant roles 
in the regulation of synaptic transmission, myelin formation, and neuronal and glial cell 
survival (Mei and Nave, 2014). Although variations in NRG1 gene were initially 
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associated with schizophrenia [see Mostaid et al. (2016) for a review], subsequent 
studies pointed to a possible association with BD (Cao et al., 2014; Georgieva et al., 
2008; Green et al., 2005; Gutierrez-Fernandez et al., 2014), notwithstanding this 
findings has not been supported thus far by GWAS (Goes, 2016). In keeping with this 
view, a study found aberrant cleavage of the neuregulin 1 in the post mortem 
hippocampus of individuals with BD (Marballi et al., 2012). We found evidence that a 
risk NRG1 SNP (SNP8NRG221533) and its HAPICE haplotype was associated with 
greater white matter in the fornix, cingulum, para-hippocampal gyrus, and the corpus 
callosum (Cannon et al., 2012). In addition, a functional neuroimaging study found that 
individuals with BD carrying the high-risk SNP (rs35753505) of the NRG1 gene 
displayed hyperactivation of the right posterior orbitofrontal cortex compared to non-
carriers (Mechelli et al., 2012). Clearly the impact of high-risk variants of the NRG1 
gene on structural and functional brain abnormalities in individuals with BD require 
further study. 
4.8. Limitations 
The findings of this systematic review should be interpreted within its limitations. First, 
the methodological quality of included studies varied. For example, the mood state of 
participants with BD varied across studies. In addition, some studies did not include a 
HC group, while few studies did not control results for multiple comparisons. Second, 
several confounding variables should be considered (e.g., differences in length of 
illness, number of previous affective episodes, and exposure to mood stabilizing 
medications). For example, it has been suggested that hippocampal volumes in BD may 
vary as a function of the number of affective episodes in a subset of patients with 
neuroprogressive forms of the illness (Cao et al., 2017; Lim et al., 2013). Furthermore, 
the large majority of studies included in this systematic review enrolled adult samples. 
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For example, a meta-analysis indicates that hyperactivation of the amygdala across 
emotional face recognition fMRI studies is more evident in BD-youths than among BD-
adults (Wegbreit et al., 2014). Third, although our findings indicate that the effects of 
genetic variants in the risk of BD may be more readily reflected as at the brain 
structure/function level than in the disease per se, this notion has been challenged by 
some experts. For example, Flint and Munafo (2007) provides meta-analytic evidence 
that the effect sizes of illness-related genetic variants on intermediate phenotypes may 
not necessarily be larger than the ones observed for the illness phenotype. Fourth, we 
included structural and functional MRI studies, but not other imaging tools (e.g., 
positron emission tomography). Fifth, although we found promising replicated findings, 
several significant associations deserve replication. For example, converging evidence 
from both preclinical and GWAS studies have implicated ANK3 as a putative risk gene 
for BD, while recent gene imaging studies offered promising initial results (Lippard et 
al., 2016).  In addition, the reproducibility of this field deserves careful examination 
(Carter et al., 2016). Sixth, the use of pre-defined ROI-based analyses could bias some 
of the converging findings of this review. For example, the study by Chepenik et al. 
(2009) in which the Met allele of the BDNF Val66Met polymorphism was associated 
with bilateral hippocampi reduction in individuals with BD restricted their analyses to 
this brain structure. 
4.9. Implications 
This systematic review open several research implications. It has been increasingly 
recognized that neurobiological abnormalities span conventional diagnostic categories 
in psychiatry. This fact motivated the NIMH to launch the Research Domain Criteria 
(RDoC) initiative (Cuthbert and Insel, 2013), with an attempt to provide a 
complimentary research classification system for mental disorders built upon 
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dimensions of neurobiology and observable behavior, and moving towards precision 
psychiatry (Fernandes et al., 2017; Vieta, 2015). Consistent with this assumption 
several genetic risk variants seem to overlap across major mental disorders (Gatt et al., 
2015). Furthermore, a recent study investigated a large panel of brain-based biomarkers 
and included participants across the psychotic spectrum (schizophrenia, schizoaffective 
disorder, and BD), and found three distinct psychotic biotypes that did not respect 
diagnostic categories (Clementz et al., 2016). Consistently, the only replicated finding 
observed in this review is also apparent in similar studies involving schizophrenia 
samples. For example, the Val66Met BDNF polymorphism has also been associated 
with reduced hippocampi volume in schizophrenia (Notaras et al., 2015b), while a 
recent systematic review found that several putative risk genes for both BD and 
schizophrenia may influence brain structure and function in healthy control samples 
(Gurung and Prata, 2015).  Therefore, future efforts to replicate the findings of this 
systematic review could include participants with different diagnostic categories, and a 
better control of potential confounding variables (e.g. concomitant medication and 
substance use. In addition, the a priori publication of research protocols in the field of 
‘imaging genetics’ could improve its reproducibility and reduce the risk of selective 
outcome reporting (Carter et al., 2016). 
5. Conclusion 
This review synthesis indicates that the ‘gene-imaging’ research paradigm may aid in 
the identification of intermediate phenotypes, and therefore could provide more 
consistent biological mechanistic insights for BD. Variants in the CACNA1C, ANK3, 
and BDNF genes yielded the most consistent findings thus far, by applying 
neuroimaging paradigms to GWAS-emerging candidate genes. Future research efforts 
should include samples with different diagnostic categories, and the development of 
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collaborative consortia with a priori published protocols could enhance the impact of 
future efforts. However, highly robust findings are unlikely if the only source of 
candidate genes are GWAS and gene polymorphisms, and neuroimaging studies are 
particularly difficult in bipolar patients because of the influence of complex medication 
regimes. 
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Figure legends 
 
Figure 1. PRISMA flowchart of the study selection process. 
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Figure 2. Figure 2. Brain map representing the approximate locations of replicated gene-
neuroimaging findings in BD patients compared to healthy control groups. VBM studies (k=2) 
found decreased volumes of the left and right hippocampi in carriers of the Met allele of the BDNF 
Val66Met polymorphism (yellow). 
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Table 1. Studies investigating the association of genetic polymorphisms and brain structure in BD using voxel based morphometry (VBM) in 
magnetic resonance imaging (MRI). 
Author Gene Subjects, n Genetic Polymorphisms, n 
Gender, 
female, n 
(%) 
Age, years, 
mean ± SD 
Methods 
Statistically 
significant 
difference?* 
Main findings 
Cao et al. 
(2016) 
BDNF BD, 48 
HC, 60 
Met carriers, 13 
Met carriers, 19 
32 (66.6) 
39 (65.0) 
41.0 ± 12.6 
40.5 ± 12.9 
MRI 1.5T 
VBM 
ROIs: Hippocampal  
cortical/subcortical 
volume 
Yes BD patients carrying the BDNF met allele had 
smaller hippocampal volumes compared to 
HCs. 
Zeni et al. 
(2016) 
BDNF 
rs6265 
BD, 29 
 
HC, 22 
Val/Val, 19 
Met carriers, 10 
Val/Val, 12 
Met carriers, 10 
 
11 (57.8) 
3 (30.0) 
3 (25.0) 
5 (50.0) 
14.8 ± 2.2 
11.8 ± 2.5 
12.7 ± 2.6 
13.4 ± 3.4 
MRI  
VBM  
ROI: Hippocampal 
cortical volume 
No† No significant differences between BD patients 
and HCs in left or right hippocampal volumes. 
Chepenik et 
al. (2009) 
BDNF BD, 20 
 
 
HC, 18 
Val/Val, 12 
Val/Met, 7 
Met/Met, 1 
Val/Val, 12 
Val/Met, 8  
11 (55.0) 
 
 
12 (66.6) 
21-56*** 
 
 
18-58*** 
MRI 1.5T 
VBM  
ROI: Hippocampal 
cortical volume 
Yes Both hippocampal volumes were significantly 
smaller in participants with BD compared to 
HCs, and the BDNF met allele was associated 
with smaller hippocampal volumes in both 
diagnostic groups. 
Mirakhur et 
al. (2009) 
BDNF BD, 18 
HC, 18 
One or more Met alleles, 6  
One or more Met alleles, 4 
10 (55.5) 
9 (50.0) 
38.4 ± 8.4 
36.7 ± 13.2 
MRI 1.5T 
VBM  
Cortical volume, 
gyrification index 
Yes Individuals with BD carrying one or more 
BDNF met alleles showed greater losses in GI, 
an effect that correlated with GM loss in the 
left hemisphere 
Matsuo et al. 
(2009) 
BDNF BD, 42 
 
HC, 42 
Val/Val, 24 
Val/Met, 18 
Val/Val, 29 
Val/Met, 13 
19 (79.1) 
14 (77.8) 
19 (65.5) 
8 (61.5) 
36.1 ± 9.3 
35.2 ± 9.7 
35.4 ± 10.5 
34.2 ± 10.4 
MRI 1.5T 
VBM  
ROIs: dlPFC, ACG, and 
hippocampus GM 
volumes 
Yes Anterior CG GM volumes significantly smaller 
in Val/Met BD compared to Val/Val BD  
Smaller left dlPFC GM volumes in Val/Met 
compared to Val/Val subjects within BD and 
HC groups. 
Benedetti et 
al. (2014) 
5-HTTLPR BD, 136 L/L, 45 
L/S, 68 
S/S, 23 
32 (71.1) 
42 (61.7) 
19 (82.6) 
45.9 ± 10.9 
46.1 ± 12.2 
48.5 ± 13.6 
MRI 3.0T 
VBM  
ROI: Hippocampal GM 
No Exposure to early stress correlated with GM 
volumes in the right prefrontal cortex 
(Brodmann area 46) in S carriers only. 
Scherk et al. 
(2009b) 
5-HTTLPR BD, 37 
 
L/L, 8 
S carriers, 29 
4 (50.0) 
15 (51.7) 
39.8 ± 14.1 
45.1 ± 11.8 
MRI 1.5T 
VBM  
Yes S carriers showed a relatively increased volume 
of the right amygdala compared to homozygous 
45 
 
HC, 37 L/L, 18 
S carriers, 19 
15 (83.3) 
7 (36.8) 
39.6 ± 15.1 
42.3 ± 10.8 
ROI: Amygdala GM 
volume 
L-allele carriers irrespective of diagnostic 
status.  
Wolf et al. 
(2014) 
CACNA1C BD, 28 
 
HC, 16 
A/A+A/G, 16 
G/G, 12 
A/A+A/G, 8 
G/G, 8 
(rs1006737) 
6 (37.5) 
7 (58.3) 
4 (50.0) 
6 (75.0) 
43.9 ± 13.0 
 
33.7 ± 13.4 
MRI 1.5T 
VBM  
ROI: Amygdala GM 
volume 
No† The authors found that the amygdala volume 
was influenced by CACNA1C genotype in BD 
but did not reach statistical significance. 
Soeiro-de-
Souza et al. 
(2012) 
CACNA1C BD, 39 
 
 
HC, 40 
Met/Met, 4 
Val/Met, 20 
Val/Val, 15 
Met/Met, 3 
Val/Met, 15 
Val/Val, 22 
24 (61.5) 
 
 
20 (50.0) 
32.9 ± 10.9 
 
 
25.9 ± 5.8 
MRI 3.0T 
VBM  
ROI: Amygdala and 
hippocampal GM 
volumes 
No† The CACNA1C genotype had no significant 
influence on amygdala or hippocampus 
volumes in either groups. 
Perrier et al. 
(2011b) 
CACNA1C 
Rs1006737 
BD, 41 
 
HC, 50 
A/A+A/G, 24 
G/G, 17 
A/A+A/G, 22 
G/G, 28 
10 (41.6) 
11 (64.7) 
7 (31.8) 
16 (57.1) 
44.4 ± 12.3 
44.1 ± 11.5 
35.6 ± 12.7 
34.4 ± 13.7 
MRI 1.5T 
VBM  
ROI: Basal ganglia, 
hypothalamus and 
amygdala GM volumes 
Yes BD patients carrying the risk allele had smaller 
left putamen than healthy controls. 
Benedetti et 
al. (2015b) 
GSK-3β BD, 150 A/A, 62 
A/G, 68 
G/G, 20 
40 (64.5) 
14 (20.5) 
14 (70.0) 
46.2 ± 11.5 
44.9 ± 11.6 
46.9 ± 10.8 
MRI 3.0T 
VBM  
Whole-brain GM volume 
No GSK-3β rs334558*G carriers and the long-term 
administration of lithium were synergistically 
associated with increased GM volumes in the 
right frontal lobe, including the boundaries of 
subgenual and OFC.  
Poletti et al. 
(2014) 
EAAT2 BD, 86 G/G, 14 
G/T, 43 
T/T, 29 
56 (65.1) 46.4 ± 12.7 
45.3 ± 11.0 
45.0 ± 12.6 
MRI 3.0T 
VBM  
ROI: Hippocampal GM 
volume 
No The effect of SLC1A2–181A > C revealed 
itself only among patients exposed to lower 
levels of ACE, with T/T homozygotes showing 
the lowest and G/G the highest hippocampal 
GM volume. 
Kittel-
Schneider et 
al. (2015) 
DGKH BD, 30 
 
HC, 18 
No GAT, 15 
>= 1 GAT, 15 
No GAT, 13 
>= 1 GAT, 5 
9 (60.0) 
6 (40.0) 
10 (76.9) 
2 (40.0) 
42.1 ± 12.4 
45.8 ± 12.4 
31.0 ± 11.3 
39.4 ± 15.5 
MRI 1.5T 
VBM  
ROI: Amygdala GM 
volume 
Yes There was a significant association of the 
DGKH risk haplotype with increased left 
amygdala volume in BD, but not in HCs. 
Cannon et al. 
(2012) 
NRG1 
 
HAP 
BD, 33 
 
 
T/T, 9 
C carriers, 18 
Arh1, 8 
6 (67.0) 
11 (61.0) 
5 (63.0) 
37.0 ± 11.0 
42.0 ± 11.0 
44.0 ± 11.0 
MRI 1.5T 
VBM  
Whole-brain WM volume 
Yes The NRG1 SNP and the HAPICE haplotype 
were associated with abnormal WM volume in 
the BD group in the fornix, cingulum and PHG 
circuit 
46 
 
 
CNP 
 
MOG 
 
NRG1 
 
HAP 
 
CNP 
 
MOG 
 
 
 
 
 
HC, 39 
Arh0, 23 
G/G, 16 
A carriers, 14 
G/G, 19 
C carriers, 11 
T/T, 10 
C carriers, 27 
Arh1, 11 
Arh0, 26 
G/G, 21 
A carriers, 16 
G/G, 21 
C carriers, 15 
 
14 (61.0) 
10 (63.0) 
9 (64.0) 
13 (68.0) 
6 (55.0) 
8 (80.0) 
11 (41.0) 
4 (34.0) 
15 (58.0) 
9 (43.0) 
8 (50.0) 
10 (48.0) 
7 (47.0) 
41.0 ± 12.0 
40.0 ± 12.0 
41.0 ± 12.0 
41.0 ± 12.0 
40.0 ± 10.0 
44.0 ± 15.0 
40.0 ± 15.0 
36.0 ± 13.0 
43.0 ± 16.0 
39.0 ± 14.0 
45.0 ± 17.0 
45.0 ± 12.0 
34.0 ± 16.0 
NRG1 (SNP8NRG221533): C carriers > T/T in 
CG/PHG, splenium and anterior CC 
HAPICE haplotype: Arh0 < Arh1 in Fornix, 
caudate, posterior CG 
MOG (rs2857766): HC G/G > C carriers in 
CST, MCP, ICP 
Papiol et al. 
(2008) 
IL-1β BD, 20 
 
HC, 45 
Non carriers, 8 
Allele*2 carriers, 20 
Not reported  
10 (50.0) 
 
21 (46.6) 
43.4 ± 11.7 
 
29.4 ± 9.0 
MRI 1.5T 
VBM  
Whole-brain WM and 
GM volumes; 
ROIs: dlPFC GM, STG 
GM, hippocampus GM 
and LV 
Yes A -511C/T polymorphism (rs16944) of IL-1β 
gene was associated with whole-brain and left 
dlPFC GM deficits in BD patients. 
Tesli et al. 
(2013) 
ANK3 
CACNA1C 
ODZ4 
SYNE1 
BD, 121 
HC, 219 
ANK3 (rs9804190, 
rs10994336 rs10994397 
rs1938526)** 
CACNA1C (rs1006737, 
rs4765913)** 
ODZ4 (rs12576775, 
rs2175420)** 
SYNE1 (rs9371601)** 
71 (58.6) 
102 (46.5) 
 
35.8 ± 11.5 
35.9 ± 9.7 
MRI 1.5T 
VBM  
Whole-brain GM volume 
No There were no significant associations between 
risk SNPs and structural brain alterations in 
BD. 
Zuliani et al. 
(2009) 
DAOA BD, 38 
 
 
 
 
 
M23 CC, 10 
M23 CT, 16 
M23 TT, 12 
M24 AA, 10 
M24 AT, 18 
M24 TT, 9 
7 (70.0) 
7 (43.7) 
5 (41.6) 
7 (70.0) 
7 (38.8) 
4 (44.4) 
38.9 ± 11.0 
41.1 ± 11.4 
37.5 ± 7.7 
41.7 ± 10.9 
40.5 ± 11.1 
37.1 ± 7.8 
MRI 1.5T 
VBM  
Whole-brain; 
ROIs: temporal lobe and 
amygdala-hippocampal 
complex GM volumes 
Yes Both M23 and M24 were associated with 
reductions of GM density within left TP 
(CC<CT<TT) in the BD group.  M23 was also 
associated with reductions in right amygdala 
GM density. 
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* Risk between BD carriers of the risk allele and healthy controls or BD non-carriers of the risk allele. Significant interactions considering only clinical symptoms 
scores or medication use were not considered. 
** Frequencies or N not reported 
*** Mean and SD not reported 
† Small sample size was considered a limitation in the original report  
†† Limitations were not reported 
HC, 81 M23 CC, 25 
M23 CT, 38 
M23 TT, 18 
M24 AA, 26 
M24 AT, 38 
M24 TT, 17 
12 (48.0) 
17 (44.7) 
10 (55.5) 
13 (50.0) 
16 (42.1) 
10 (58.8) 
34.4 ± 10.3 
35.0 ± 11.6 
32.6 ± 8.5 
34.5 ± 10.4 
35.0 ± 11.6 
33.3 ± 8.8 
Bergmann et 
al. (2013) 
ZNF804A BD, 85 
 
HC, 152 
rs13393271, 81 
rs359878, 85 
rs13393271, 148 
rs359878, 151 
43 (53.0) 
 
73 (48.0) 
36.1 ± 11.0 
 
35.9 ± 9.6 
MRI 1.5 T 
VBM 
Whole-brain cortical 
thickness 
No†† There were no associations between any of the 
SNPs and cortical thickness measures in HC or 
BD groups. 
Oertel-
Knochel et 
al. (2015) 
7 risk SZ 
SNPs from a 
GWAS  
 
BD, 20 
HC, 38 
MIR137 (rs1625579) 
CCDC68 (rs12966547) 
CNNM2 (rs7914558) 
NT5C2 (rs111915801) 
MMP16 (rs7004633) 
CSMD1 (rs10503253) 
PCGEM1 (rs17662626)**  
11 (55.0) 
20 (52.6) 
39.0 ± 12.1 
37.1 ± 11.1 
MRI 3.0 T 
VBM  
Whole-brain WM volume 
No Increased additive genetic risk for SZ was 
associated with reduced white matter volume in 
a group of participants consisting of healthy 
individuals, SZ first-degree relatives, SZ 
patients and BD patients, but not in diagnostic 
groups separately. 
Bakken et al. 
(2011) 
GWAS BD, 97 
HC, 181 
None 53 (55.0) 
87 (48.0) 
35.7 ± 11.1 
35.9 ± 9.5 
MRI 1.5T 
VBM  
Whole-brain cortical 
thickness 
No No SNP associations were genome-wide 
significant in the BD group. 
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Table 2. Studies investigating the association of genetic polymorphisms and brain structure in BD using diffusion tensor imaging (DTI) in 
magnetic resonance imaging (MRI). 
Author Gene Subjects, n Genetic Polymorphisms, n 
Gender, 
female, n 
(%) 
Age, years, 
mean ± SD 
Methods 
Statistically 
significant 
difference?* 
Main findings 
Diffusion Tensor Imaging (DTI) and VBM 
Ota et al. 
(2016) 
ANK3 
rs10761482 
BD, 43 
 
HC, 229 
C/C, 24 
T carriers, 19 
C/C, 133 
T carriers, 96 
8 (33.3) 
13 (68.4) 
94 (70.6) 
74 (77.0) 
40.8 ± 9.9 
35.9 ± 7.9 
45.8 ± 15.8 
45.3 ± 15.6 
MRI 1.5T 
DTI/VBM  
Whole-brain GM volume 
and WM FA 
Yes (DTI) Decreased FA was found in the forceps minor 
in non-T-allele BD patients compared with the 
T-carrier BD group. 
No main effect of genetic variations were 
found on the GM volume and the genotype-
by-diagnosis interaction. 
Lippard et 
al. (2016) 
ANK3 
rs9804190 
BD, 90 
 
HC, 97 
C/C, 52 
T carriers, 38 
C/C, 56 
T carriers, 41 
35 (67.0) 
26 (68.0) 
28 (50.0) 
23 (53.0) 
27.5 ± 12.2 
26.5 ± 11.1 
23.9 ± 9.0 
28.6 ± 12.9 
MRI 3.0 T 
DTI/VBM  
Whole-brain analysis 
ROIs: amygdala and OFC 
GM; whole-brain and UF 
FA 
Yes (DTI) BD subjects carrying the T (risk) allele 
showed decreased FA compared with other 
subgroups, independent of age within the UF. 
Compared with BD CC homozygotes, BD T-
carriers had lower FA in the UF and anterior 
CG bilaterally, in dorsomedial frontal WM, in 
left temporoparietal WM and in posterior 
dorsomedial WM, among others. 
DTI         
Benedetti et 
al. (2015a) 
5-HTTLPR 140, BD L/L, 47 
S carriers, 93 
32 (68.0) 
36 (38.7) 
46.4 ± 20.7 
30.3 ± 10.2 
MRI 3.0T 
DTI  
Whole-brain analysis 
Yes S carriers showed significantly increased 
radial and mean diffusivity in several brain 
WM tracts (right posterior CG, left anterior 
CG, CCb, CCg and right posterior CR) 
Benedetti et 
al. (2013) 
GSK-3β 70, BD T/T, 26 
C carriers, 44 
19 (73.0) 
31 (70.0) 
45.7 ± 11.8 
45.7 ± 11.4 
MRI 3.0T 
DTI  
Whole-brain analysis 
Yes The rs334558*C carriers and the long-term 
use of lithium were associated with increased 
axial diffusivity in several WM fiber tracts 
(CC, FM, anterior CG and posterior CG 
bilaterally, including its hippocampal part, left 
superior and inferior LF, left inferior FOF, left 
posterior TR, bilateral superior and posterior 
CR, and bilateral CST). 
Kuswanto et 
al. (2013) 
GRIN2B BD, 14 
 
 
G/G, 1 
G/T, 2 
T/T, 11 
4 (18.1) 
 
 
36.9 ± 12.2 
 
 
MRI 3.0T 
DTI  
Whole-brain analysis 
Yes Compared to G allele, brain FA values were 
significantly lower in BD patients carrying the 
T allele in bilateral frontal regions, left parietal 
region, left occipital region, right occipital 
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* Risk between BD carriers of the risk allele and healthy controls or BD non-carriers of the risk allele. Significant interactions considering only clinical symptoms 
scores or medication use were not considered. 
† Sample size was not mentioned as a limitation in the original report. 
  
HC, 22 G/G, 3 
G/T, 5 
T/T, 14 
11 (50.0) 32.7 ± 12.3 
 
region and left CG. 
Mallas et al. 
(2016a) 
CACNA1C 
rs1006737 
BD, 43 
 
 
HC, 124 
A/A, 15 
A/G, 15 
G/G 13 
A/A, 17 
A/G, 51 
G/G, 56 
25 (58.1) 
 
 
57 (46.0) 
41.1 ± 12.3 
 
 
35.8 ± 13.4 
MRI 1.5T 
DTI  
Whole-brain analysis 
No† There was no significant main effect of the 
CACNA1C genotype on FA. In BD patients, 
the ZNF804A rs1344706 risk genotype 
increased the magnitude of the effect of the 
CACNA1C risk genotype, but the association 
was no longer significant after controlling for 
age. 
Mallas et al. 
(2016b) 
ZNF804A 
rs1344706 
BD, 43 
 
 
HC, 124 
A/A, 19 
A/C, 16 
C/C, 8 
A/A, 59 
A/C, 51 
C/C, 14 
25 (58.1) 
 
 
57 (46.0) 
41.0 ± 12.3 
 
 
35.7 ± 13.4 
MRI 1.5T 
DTI  
Whole-brain analysis 
No No areas with a significant diagnosis by 
genotype interaction were found. 
 
Poletti et al. 
(2016) 
SREBF1 
rs11868035 
 
SREBF2 
rs1052717 
BD, 93 A/A, 10 
A/G, 45 
G/G, 38 
A/A, 27 
A/G, 39 
G/G, 27 
5 (50.0) 
29 (64.4) 
28 (73.7) 
19 (70.4) 
25 (64.1) 
18 (66.7) 
44.8 ± 13.8 
46.1 ± 12.1 
43.8 ± 9.2 
43,8 ± 12.1 
45.7 ± 11.3 
45.3 ± 10.3 
MRI 3.0T 
DTI  
Whole-brain analysis 
Yes No effect on DTI measures of WM integrity 
was observed for SREBF1 polymorphism. The 
SREBF2 rs1052717 polymorphism A/A 
genotype had increased radial diffusivity 
compared to A/G and G/G, and the A/A 
genotype had reduced FA compared to G 
carriers in cingulum, corpus callosum, 
superior and inferior longitudinal fasciculi, 
and anterior thalamic radiation. 
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Table 3. Studies investigating the association of genetic polymorphisms and brain activity in BD using functional magnetic resonance imaging 
(fMRI) during emotional tasks. 
Author Gene Subjects 
Genetic Polymorphism, 
n 
Gender, 
female, n (%) 
Age, years, 
mean ± SD 
Methods 
Statistically 
significant 
difference?* 
Main findings 
Tesli et al. 
(2013) 
CACNA1C BD, 66 
 
HC, 123 
A/A+A/G, 34 
G/G, 32 
A/A+A/G, 71 
G/G, 52 
18 (52.9) 
20 (62.5) 
31 (43.7) 
23 (44.2) 
34.2 ± 10.0 
35.5 ± 11.4 
34.0 ± 7.8 
35.3 ± 10.4  
fMRI 1.5T 
Emotional stimuli 
(negative faces) 
paradigm) 
ROI: Bilateral 
amygdala 
Yes Carriers of the risk allele had increased activation in the 
left amygdala in the BD group.  
Radua et al. 
(2013) 
CACNA1C BD, 20 
HC, 20 
Rs1006737 GG, AG and 
AA 
Letter to the editor, N not 
reported 
8 (40.0) 
10 (50.0) 
43.0 ± 14.0 
42.0 ± 12.0 
fMRI (Tesla not 
reported) 
Fearful faces 
ROIs: MFG, left 
putamen and left 
amygdala  
No†† MTG out-degree connectivity gradually decreased with 
the number of CACNA1C risk alleles (GG<AG<AA) in 
BD and HC groups. 
Jogia et al. 
(2011) 
CACNA1C BD, 41 
 
 
HC, 50 
GG, 17 
AG, 19 
AA, 5 
GG, 28 
AG, 18 
AA, 4 
21 (51.2) 
 
 
23 (46.0) 
44.3 ±11.9 
 
 
34.9 ±13.2 
fMRI 1.5T 
Facial affect 
recognition task 
(fearful vs neutral 
faces) 
ROIs: PFC, ACG, 
amygdala and 
hippocampus 
Yes Independent of diagnostic group, the right amygdala 
showed greater activation during fear-face recognition 
relative to neutral faces in AA/AG compared to GG 
individuals. The right vlPFC expressed reduced 
activation in individuals with the high-risk allele 
compared with those with the low-risk variant in BD 
patients. 
Dima et al. 
(2013) 
CACNA1C 
 
 
 
ANK3 
BD, 41 
 
HC, 46 
 
BD, 41 
 
HC, 46 
A/A+A/G, 17  
G/G, 24  
A/A+A/G, 25  
G/G, 21  
T/T+C/T, 16  
C/C, 25  
T/T+C/T, 14  
C/C, 32  
11 (64.7) 
10 (41.6) 
9 (36.0) 
9 (42.8) 
7 (43.7) 
14 (56.0) 
7 (50.0) 
14 (43.7) 
44.4 ± 12.3 
44.1 ± 11.6 
36.3 ± 10.4 
38.1 ± 13.4 
42.0 ± 10.7 
43.3 ± 2.3 
40.6 ± 12.2 
39.3 ± 12.3 
fMRI 1.5T 
Facial affect 
paradigm 
ROIs: IOG, FG, 
amygdala, vlPFC 
and whole-brain 
analysis 
 
 
Yes BD carriers of either genetic risk variant exhibited 
pronounced reduction in vlPFC activation compared to 
HCs.  
Barzman et 
al. (2014) 
TNF BD, 10 TNF gene expression 
levels, 10 
5 (50.0) 15.0 ± 1.0 fMRI 4.0T 
Posner Task 
Yes Expression of 11 TNF-related genes were significantly 
correlated with activation of amygdala or anterior CG 
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* Comparisons between BD carriers of the risk allele and healthy controls or BD non-carriers of the risk allele. Significant interactions considering only clinical 
symptoms scores or medication use were not considered. 
** Polygenic risk score (PGR) is calculated in each individual by aggregating variation across GWAS loci nominally associated with BD into a quantitative score (Dima 
and Breen, 2015). The study used a PGR based on 16,691 SNPs with p < 0.1. It is presented as mean (SD). 
† Sample size was considered a limitation in the original report 
(Selective 
attention task to 
negative 
emotions) 
Whole-brain 
analysis 
during the affective Posner Task.  
Lelli-Chiesa 
et al. (2011) 
COMT  BD, 40 
 
HC, 50 
Val/Val, 11 
Val/Met+Met/Met, 29 
Val/Val, 15 
Val/Met+Met/Met, 35 
21 (52.5) 
 
24 (48.0) 
 
44.0 ± 11.9 
 
34.9 ± 13.2 
 
fMRI 1.5T 
Sad facial affect 
discrimination 
task 
ROIs: Amygdala 
and ventral PFC 
No†† No significant diagnosis × genotype interaction was 
detected in the BD group. 
Liu et al. 
(2010) 
GWAS BD, 39 
HC, 29 
 
rs2023454 SNP DOK5 
gene 
24 
18 
 
15.0 ± 2.8 
13.0 ± 2.9 
 
fMRI 3.0T 
Face-processing 
paradigm  
ROI: Amygdala 
No† No significant main effect of diagnosis and no 
significant diagnosis × genotype interaction was 
detected. In both the BD and HC samples the  
rs2023454 SNP of the DOK5 gene was significantly 
associated with right amygdala activation under the 
hostility contrast.  
Shah et al. 
(2009) 
5-HTTLPR BD, 30  
 
HC, 48 
 
 
L/L, 10 
S carriers, 20 
L/L, 14 
S carriers, 34 
 
7 (70.0) 
13 (65.0) 
6 (42.8) 
22 (64.7) 
 
36.9 ± 16.9 
29.4 ± 11.0 
26.1 ± 9.3 
29.1 ± 10.3 
 
fMRI 3.0T 
Emotional face 
paradigm 
ROI: Ventral 
ACG 
Yes During fear and happy face processing, ventral ACG 
activation was significantly lower in the BD compared 
to the HC group, and in S carriers compared to L/L 
individuals within both HC and BD groups 
Dima et al. 
(2016) 
Polygenic 
risk score 
(GWAS)** 
BD, 41 
 
HC, 46 
0.37 (0.04) 
 
0.32 (0.06) 
21 (51.2) 
 
21 (45.7) 
44.3 ± 11.9 
 
40.3 ± 13.2 
fMRI 1.5T 
Facial affect 
paradigm; 
2-back task  
Whole-brain 
analysis 
 
No The PGR was associated with task-related changes in 
the BOLD signal in both the BD and HC groups. No 
significant correlation between the PGR score and the 
signal changes observed in BD patients during the facial 
affect paradigm was found (increased activation of ACG 
and decreased activation of the right superior frontal 
gyrus). In the 2-back task, no effect of group was noted 
and no correlation of the PGR score and group was 
observed in the task-related activation. 
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†† Sample size was not mentioned as a limitation in the original report 
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Table 4. Studies investigating the association of genetic polymorphisms and brain activity in BD using functional magnetic resonance imaging 
(fMRI) during verbal and working memory tasks. 
Author Gene Subjects 
Genetic Polymorphism, 
n 
Gender, 
female, n (%) 
Age, years, 
mean ± SD 
Methods 
Statistically 
significant 
difference?* 
Main findings 
Delvecchio et 
al. (2015) 
ANK3 BD, 41 
 
 
 
 
 
HC, 46 
T/T+C/T, 16 
C/C, 25 
(Rs10994336) 
C/C, 21 
T/T+C/T, 20 
(Rs9810490) 
T/T+C/T, 14 
C/C, 32 
(Rs10994336) 
C/C, 28 
T/T+C/T, 18 
(Rs9810490) 
 
7 (43.7) 
14 (56.0) 
 
13 (61.9) 
9 (45.0) 
 
7 (50.0) 
14 (43.7) 
 
14 (50.0) 
8 (44.4) 
 
42.0 ± 10.7 
43.3 ± 12.3 
 
43.5 ± 12.5 
44.8 ± 9.5 
 
40.6 ± 12.2 
39.3 ± 12.3 
 
40.1 ± 13.2 
40.1 ± 11.9 
fMRI 1.5T 
N-back task 
Whole-brain 
analysis 
Yes For the ANK3 rs10994336, the risk T-allele was 
associated with increased activation in the right ACG 
and left PCG in BD patients compared to HCs.  
For the ANK3 rs9804190, the risk C-allele homozygotes 
showed increased activation in right ACG in BD 
patients compared to HCs.  
 
Prata et al. 
(2011) 
DISC1 BD, 35 
 
HC, 53 
 
Ser/Ser, 17 
Cys Carriers, 18 
Ser/Ser, 26 
Cys Carriers, 27 
11 (61.1) 
10 (55.5) 
12 (46.1) 
15 (55.5) 
38.1 ± 13.3 
40.9 ± 11.2 
31.7 ± 11.1 
37.8 ± 9.9 
fMRI 1.5T 
Verbal fluency 
test 
ROIs: Left 
middle/superior 
frontal gyrus and 
whole-brain 
analysis 
No No significant effect of Cys704Ser was detected. 
Chakirova et 
al. (2011) 
DISC1  
 
BD, 36 
 
HC, 34 
T/T, 16 
C/C+C/T, 20 
T/T, 16 
C/C+C/T, 18 
(rs821633) 
14 (38.8) 
 
25 (75.7) 
39.3 ± 10.8 
 
37.3 ± 12.1 
fMRI 1.5T 
Verbal initiation 
and Sentence 
completion tasks 
Whole-brain 
analysis 
Yes Decreased activation in BD carriers of SNP rs821633 in 
the right IPL and left CG compared to non-carriers. 
Mechelli et 
al. (2012) 
DAOA 
(rs746187)  
BD, 33 
 
A/A, 10 
A/G+G/G, 23 
7 (70.0) 
15 (65.2) 
34.6 ± 13.1 
39.2 ± 11.7 
fMRI 
1.5T 
Yes DAOA AA genotype was associated with greater 
deactivation (i.e. repetition > verbal fluency) during task 
performance than the AG/GG genotype in patients with 
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* Comparisons between BD carriers of the risk allele and healthy controls or BD non-carriers of the risk allele. Significant interactions considering only clinical 
symptoms scores or medication use were not considered. 
† Sample size was considered a methodological limitation in the original report. 
†† Sample size was not mentioned as a limitation in the original report.  
 
 
DAAO 
(rs2111902) 
HC, 47 A/A, 22 
A/G+G/G, 25 
T/T, 27 
T/G+G/G, 20 
T/T, 16 
T/G+G/G, 17 
11 (50.0) 
12 (48.0) 
14 (51.8) 
9 (45.0) 
10 (62.5) 
11 (64.7) 
32.9 ± 8.2 
34.8 ± 11.8 
34.5 ± 10.3 
33.2 ± 10.3 
39.1 ± 11.0 
38.5 ± 12.0 
Verbal fluency 
paradigm 
Whole-brain 
analysis 
BD, but not in HC in left precuneus.  There were no 
regions showing a significant diagnosis by DAAO 
genotype interaction.  
Papagni et 
al. (2011) 
DAAO BD, 33 
 
HC, 48 
 
C/C, 19 
C/T+T/T, 14 
C/C, 29 
C/T+T/T, 19 
11 (57.8) 
9 (64.2) 
14 (48.2) 
10 (52.6) 
40.1 ± 12.2 
37.0 ± 11.9 
34.9 ± 10.5 
33.5 ± 10.9 
fMRI 1.5T Verbal 
fluency paradigm 
Whole-brain 
analysis 
No No significant effects of diagnosis or of genotype in 
comparisons involving BD patients. 
Ham et al. 
(2016) 
BclI BD, 26 
 
HC, 32 
G/G, 11 
C carriers, 15 
G/G, 18 
C carriers, 14 
 
11 (100.0) 
10 (66.6) 
12 (66.6) 
10 (71.4) 
29.6 ± 8.5 
33.6 ± 9.0 
34.5 ± 4.7 
32.5 ± 6.0 
fMRI 3.0T 
Reward test 
paradigm 
Whole-brain 
analysis 
No† No significant main effects of genotype, diagnosis or 
reward condition involving BD patients solely. 
Mechelli et 
al. (2008) 
NRG1 BD, 29 
 
HC, 45 
 
 
T/T, 16 
C/T, 13 
T/T, 25 
C/T, 20 
 
12 (75.0) 
8 (61.5) 
12 (48.0) 
12 (60.0) 
 
35.1 ± 12.6 
41.1 ± 9.8 
35.7 ± 9.7 
34.6 ± 12.2 
 
fMRI 1.5T 
Verbal fluency 
task 
Whole-brain 
analysis 
Yes The high-risk variant of NRG1 was associated with 
greater deactivation in the left precuneus in both HC and 
BD. Right posterior OFC expressed increased activation 
in individuals with the high-risk variant in the BD 
group.   
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Table 5. Summary of findings of reported genes and statistically significant differences between BD patients with high-risk genetic polymorphisms 
and healthy controls (HCs). 
Gene Name Function 
Reported 
Polymorphisms 
N of 
studies 
Polymorphism 
with positive 
results 
Method 
Neuroimaging finding 
Functional 
paradigm or 
DTI 
parameter 
used 
Increased Decreased 
CACNA1C L-type calcium 
channel α1C 
subunit  
Voltage-dependent Ca2+ channels 
rapidly increase intracellular Ca2+ 
concentration after depolarization, 
initiating a host of responses, 
including neurotransmitter release and 
changes in gene expression (Gargus, 
2009) 
rs1006737, G to A  4 Rs1006737 (Risk 
allele A) 
VBM  L Putamen (v)  
   Rs1006737 (Risk 
allele A) 
fMRI L Amygdala (f)  Emotional 
face task 
   Rs1006737 (Risk 
allele A) 
fMRI R Amygdala (f) R vlPFC (f) Emotional 
face task 
   Rs1006737 (Risk 
allele A) 
fMRI  R vlPFC/ 
L vlPFC (f) 
Emotional 
face task 
ANK3 Ankyrin 3 Encodes ankyrin 3, a large protein 
involved in coordinated assembly of 
ion transporters and cell adhesion 
molecules at axon initial segments 
and nodes of Ranvier in myelinated 
nerves (Linke et al., 2011) 
rs10994336 
rs9804190 
rs10761482  
4 rs10761482 
(cytosine [C] / 
thymine [T]; (risk 
allele C) 
DTI  R Forceps minor/ 
L Forceps minor  
FA 
    rs9804190 (T 
carriers [risk]) 
DTI  R UF/ 
L UF/ 
R Dorsal ACG/ 
L Dorsal ACG/ 
L Temporoparietal 
region/ 
L Dorsal CG/ 
L Parietooccipital 
region/ 
R Parietal region WM  
FA 
    rs10994336 (risk 
allele T) 
fMRI R ACG/ 
L PCG (f) 
 N-back task 
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    rs9804190, risk 
allele C) 
fMRI R ACG (f)  N-back task 
                                  rs10994336; risk 
allele T 
fMRI  R vlPFC/ 
L vlPFC (f) 
Emotional 
face task  
BDNF Brain-derived 
neurotrophic 
factor 
Small protein of the neurotrophin 
family that regulates various brain 
functions; it has been implicated in 
modulation of hippocampal plasticity 
and hippocampal-dependent memory 
(Lu and Gottschalk, 2000) 
Val66Met (rs6265) 3 Met carriers VBM  R Hippocampus/ 
L Hippocampus  
 
    Met carriers VBM  R Hippocampus/ 
L Hippocampus  
 
    Met carriers VBM  R ACG/L ACG/ 
L dlPFC  
 
5-HTTLPR Serotonin 
transporter 
polymorphism  
Polymorphism in the upstream 
regulatory region of the gene – a 44-
bp deletion/insertion (5-HTTLPR) 
located at the 5'-flanking regulatory 
region of the gene coding for the 
serotonin transporter (SLC6A4) on 
chromosome 17q11.2. In vitro studies 
evidenced that the basal activity of the 
long (l) variant was more than twice 
that of the short (s) form of the 5-
HTTLPR, suggesting that serotonin 
transporter gene transcription is 
modulated by variants of the 5-
HTTLPR with the s allele 
corresponding to low serotonin uptake 
activity (Heils et al., 1996) 
Long (l) and short (s) 
variants (risk) 
3 s carriers VBM R Amygdala (v)   
    s carriers DTI R PCG/ 
L ACG/CCb/CCg/ 
R posterior CR  
 RD and MD 
    s carriers fMRI  R Ventral ACG/ 
L Ventral ACG 
Emotional 
face task  
NRG1 Neuregulin-1  Encodes a family of signaling proteins 
in various tissues of the body with 
NRG1 expression being highest in the 
brain. In the nervous system, NRG1 
proteins have been implicated in 
numerous functions, including 
neuronal migration, synapse 
formation and receptor expression as 
well as myelination by regulating 
SNP8NRG243177 
(rs6994992) 
SNP8NRG221533 
(rs35753505) 
2 SNP8NRG221533 
(rs35753505) C 
carriers (high risk) 
VBM L CG/ 
L PHG/CCs/ACC 
  
    SNP8NRG221533 
(rs35753505) C 
carriers (high risk) 
fMRI R posterior OFC  Verbal 
fluency task 
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oligodendrocyte proliferation and 
differentiation (Winterer et al., 2008) 
G72 D-amino acid 
oxidase 
activator 
G72 has been associated with 
modulation of NMDA receptor 
function and with regulation of 
mitochondrial function and dendritic 
branching (Zuliani et al., 2009) 
SNPs M23C/T and 
M24A/T  
2 M23 and M24 T 
carriers 
VBM  L TP/ 
R Amygdala 
 
  SNP rs746187A/G  SNP rs746187 
A/A 
fMRI  L Precuneus Verbal 
fluency 
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DISC1 Disrupted-in-
schizophrenia 1  
Expressed predominantly within the 
hippocampus and codes for a protein 
with a globular N-terminus domain, a 
coiled C-terminus domain, and 
several coiled-coil domains. The 
functional role of DISC1 is largely 
unknown, but these distinct domains 
allow DISC1 protein to interact with 
both centrosomal and cytoskeletal 
proteins as well as with membrane 
associated and signal transduction 
proteins (Callicott et al., 2005) 
Various risk variants 
(rs1538979, rs821577, 
rs821633, rs821616 
[Ser704Cys], rs6675281 
[Leu607Phe] and 
rs1411771) (Chakirova 
et al., 2011) 
1 rs821633, risk 
allele C 
fMRI  R IPL/ 
L CG 
Verbal 
initiation and 
Sentence 
completion 
tasks 
DGKH Diacylglycerol 
kinase eta 
(DGKη) 
The DGKη enzime plays an important 
role in the inositol triphosphate 
second messenger pathway by 
catalyzing the metabolism of 
diacylglycerol (DAG) to phosphatidic 
acid. DAG is an activator of many 
isoforms of protein kinase C (PKC). 
Therefore, DGKH regulates the 
activity of PKC isoforms which play a 
key role in various signaling pathways 
(Kittel-Schneider et al., 2015) 
Risk haplotypes 
(rs9315885, rs1012053, 
rs1170191, TAC), risk 
haplotype (rs994856/ 
rs9525580/rs9525584 
GAT) and/or risk 
polymorphisms in 
DGKH (rs994856, 
rs9525580, rs9525584, 
rs9315885) 
1 rs994856/ 
rs9525580/rs9525
584 GAT (risk 
haplotype) 
VBM L Amygdala   
HAPICE NRG1 HAPICE 
(deCODE) 
haplotype 
It is a core haplotype of NRG1 
consisting of five SNPs and two 
microsatellites (Cannon et al., 2012) 
Arh0 (no copies of the 
haplotype): no risk Arh1 
(1 or 2 copies of the 
haplotype): risk 
1 Arh1: risk VBM R Fornix/ 
L Caudate/ 
L PCG 
  
IL-1β Interleukin-1 
beta 
Encodes for interleukin-1 beta (IL-
1β), pro-inflammatory cytokine which 
has an important role in the induction 
of the dopaminergic phenotype in 
mesencephalic neuronal precursors as 
well as in the regulation of dendrite 
growth in developing cortical neurons 
(Papiol et al., 2008)  
 --511 AvaI 
polymorphic site 
(rs16944) of IL-1B gene. 
Allele*1 (511C) of IL-
1B gene completes an 
AvaI restriction site, 
while allele*2 (511T) 
gives an intact product 
1 Allele*2 carriers VBM  L dlPFC  
GRIN2B NMDA receptor 
subunit 2B 
Encodes the NR2B subunit of the 
NMDA glutamate receptor. This 
subunit is expressed in the cortical 
and medial temporal parts of the 
brain, striatum, and olfactory bulb 
Risk variant rs890 G/T 1 T allele DTI  R Frontal region/ 
L Frontal region/ 
L Parietal region/ 
L Occipital region/ 
R Occipital region/ 
FA 
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(Kuswanto et al., 2013) L CG 
TNF Tumor necrosis 
factor 
Encodes Tumor necrosis factor-alpha 
(TNFα), a cytokine involved in both 
systemic and neuro-inflammation and 
in the acute phase reaction, and may 
influence neuronal and neurochemical 
processes associated with aggression 
in preclinical and clinical studies 
(Barzman et al., 2014)  
TNF family genes 
expression (Barzman et 
al., 2014) 
1 TNF family genes 
expression levels 
(11) 
fMRI R ACG/ 
L ACG/ 
L amygdala 
 Posner Task 
(Frustrative 
non-reward 
task) 
